anti-VEGFR-2 CAR T-cell therapy VHH (Helix BioPharma)

N/A

Report date: 2025/01/26 18:32:59

Base Information

Drug Nameanti-VEGFR-2 CAR T-cell therapy VHH (Helix BioPharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionVascular endothelial growth factor receptor 2 modulators
TargetsVascular endothelial growth factor receptor 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHelix Biopharma Corp
China Registration ClassN/A

Develop Information

Active CompaniesHelix Biopharma Corp
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A